Research
Hormonal
The safety profile of tirzepatide was broadly similar across BMI and age subgroups, but drug discontinuation due to adverse events was higher in participants aged ≥ 65 years.
While generally safe, practitioners should monitor older patients closely when prescribing tirzepatide.
StrongQualifiesmedium confidence
While the safety profile of tirzepatide was broadly similar across BMI and age subgroups, drug discontinuation because of adverse events was higher in participants with a baseline age of ≥ 65 years.
Why this rating
Based on the phase 3 clinical trial data presented in the abstract.
Source
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies ( <scp>SURPASS</scp> programme)
Arihiro Kiyosue et al. · Diabetes Obesity and Metabolism · 2022
DOI 10.1111/dom.14952
rctCited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →